BMO Capital analyst Evan Seigerman lowered the firm’s price target on Mirati Therapeutics to $50 from $59 and keeps a Market Perform rating on the shares after its Q4 results. The company has reiterated confidence in their commercialization strategy for Krazati, but there is limited read-through for now given the program’s recent approval, the analyst tells investors in a research note. BMO Capital also believes that Mirati’s current valuation reflects the company’s pipeline opportunities.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
- Mirati Therapeutics reports Q4 EPS ($3.51), consensus ($3.55)
- Mirati Therapeutics price target raised to $56 from $52 at B. Riley
- Mirati Therapeutics says FDA clears IND application of MRTX1133
